Omeros Cost of Goods Sold 2010-2024 | OMER
Omeros cost of goods sold from 2010 to 2024. Cost of goods sold can be defined as the difference between beginning and ending inventories for tangible products resulting in an expense that reflects production and sales costs.
| Omeros Annual Cost of Goods Sold (Millions of US $) |
|
|---|---|
| 2024 | $0 |
| 2023 | $0 |
| 2022 | $0 |
| 2021 | $0 |
| 2020 | $0 |
| 2019 | $0 |
| 2018 | $1 |
| 2017 | $1 |
| 2016 | $1 |
| 2015 | $1 |
| 2014 | $0 |
| 2013 | $0 |
| 2012 | $0 |
| 2011 | $0 |
| 2010 | $0 |
| 2009 | $0 |
| Omeros Quarterly Cost of Goods Sold (Millions of US $) |
|
|---|---|
| 2024-12-31 | |
| 2024-09-30 | |
| 2024-06-30 | |
| 2024-03-31 | |
| 2023-12-31 | |
| 2023-09-30 | |
| 2023-06-30 | |
| 2023-03-31 | |
| 2022-12-31 | |
| 2022-09-30 | |
| 2022-06-30 | |
| 2022-03-31 | |
| 2021-12-31 | |
| 2021-09-30 | |
| 2021-06-30 | |
| 2021-03-31 | |
| 2020-12-31 | |
| 2020-09-30 | $0 |
| 2020-06-30 | $0 |
| 2020-03-31 | $0 |
| 2019-12-31 | |
| 2019-09-30 | $0 |
| 2019-06-30 | $0 |
| 2019-03-31 | $0 |
| 2018-12-31 | $0 |
| 2018-09-30 | $0 |
| 2018-06-30 | $0 |
| 2018-03-31 | $0 |
| 2017-12-31 | $0 |
| 2017-09-30 | $0 |
| 2017-06-30 | $0 |
| 2017-03-31 | $0 |
| 2016-12-31 | $0 |
| 2016-09-30 | $0 |
| 2016-06-30 | $0 |
| 2016-03-31 | $0 |
| 2015-12-31 | $0 |
| 2015-09-30 | $0 |
| 2015-06-30 | $0 |
| 2015-03-31 | $0 |
| 2014-12-31 | |
| 2014-09-30 | |
| 2014-06-30 | |
| 2014-03-31 | |
| 2013-12-31 | |
| 2013-09-30 | |
| 2013-06-30 | |
| 2013-03-31 | |
| 2012-12-31 | |
| 2012-09-30 | |
| 2012-06-30 | |
| 2012-03-31 | |
| 2011-12-31 | |
| 2011-09-30 | |
| 2011-06-30 | |
| 2011-03-31 | |
| 2010-12-31 | |
| 2010-09-30 | |
| 2010-06-30 | |
| 2010-03-31 | |
| 2009-12-31 | |
| 2009-09-30 | |
| 2009-06-30 | |
| 2009-03-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED PRODUCTS | $0.418B | $0.000B |
| Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. | |||